Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies

  1. Home
  2. Research Articles
Journal Title: 
Annals of Hematology
Primary Author: 
Panse J
Author(s): 
Panse J, Han B, Cermak J, Gonzalez Fernandez FA, Gotoh A, Kulasekararaj AG, Kyselova O, Sahin F, Scheinberg P, Schrezenmeier H, Straetmans N, Ueda Y, Chang AC, Gentile B, Stefani J, Uguen M, Röth A
Original Publication Date: 
Saturday, June 14, 2025
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/40515823/
Bone Marrow Disease(s):